Daewoong Pharmaceutical and Partners Invest in Vincier, a Parkinson’s Disease Drug Development Company Using AI Platform

On the 13th, Daewoong Pharmaceutical decided to jointly invest in Hanall Biopharma and Vincier Bioscience (hereinafter referred to as Vincier), a new drug development company for Parkinson’s disease in the United States.

With this investment as an opportunity, the three companies plan to seek cooperation opportunities using Vincier’s AI platform, such as cooperation for the development of Parkinson’s disease treatment, clinical trial design, and selection of patient candidates.

Vincire is a bio company founded in 2018 by Dr. Spring Behrouz, an authority on Parkinson’s disease, and is developing treatments for degenerative diseases caused by aging, such as Parkinson’s disease and Alzheimer’s dementia, by using its own AI platform.

When mitochondria in cells are damaged or reach the end of their lifespan, a phenomenon called ‘Mitophagy’ occurs, in which cells remove them. Vincire’s candidate aims to increase the percentage of healthy mitochondria by enhancing mitophagy activity in the body and inhibit the progression of Parkinson’s disease.

In recognition of this, it received research funds from the Michael J. Fox Foundation, a Parkinson’s disease research foundation founded by Hollywood actor Michael J. Fox, on a total of four occasions since 2019. In addition, it has received research funding from the National Institute on Aging (NIA), which selects scientists who show outstanding research performance and potential and provides research funds.

Daewoong Pharmaceutical CEO Jeon Seung-ho said, “We are very pleased to have established a close partnership with Vincier to accelerate the development of innovative treatments for aging and chronic degenerative diseases, one of Daewoong Pharmaceutical’s recent major target areas.”

Jeong Seung-won, CEO of HanAll Biopharma, said, “Vincier has the potential to completely change the existing approach to Parkinson’s disease treatment development by applying AI technology to the new drug development process.” We will continue to seek ways to cooperate in the process of developing new drugs, such as discovering candidate substances using AI.”